Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537563 · ClinicalTrials.gov registry record · Phase 3
AMS VS MOXI Ketek vs Avelox in AMS
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 351
- Enrollment target
NCT00537563 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 351 participants.
The verdict
NCT00537563, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 351 participants
- Enrollment target
Study Summary
Clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure visit, and to assess the safety of telithromycin given once daily for 5 days vs moxifloxacin given once daily for 10 days in the treatment of subjects with AMS.
Interventions
- DRUG Telithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2002-12 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00537563
The ClinicalTrials.gov registry entry for NCT00537563 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telithromycin is the first listed.
NCT00537563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00537563 about?
NCT00537563 is a clinical study titled "AMS VS MOXI Ketek vs Avelox in AMS". Clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure visit, and to assess the safety of telithromycin given once daily for 5 days vs moxifloxacin given once daily for 10 days in the treatment of subjects with AMS.
What is the current status of trial NCT00537563?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 351 participants. The study started on 2002-12. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00537563?
The interventions under investigation include: Telithromycin (DRUG).
Who is sponsoring clinical trial NCT00537563?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.